Evaluation of Serum Levels of SCD30L Ligand in Patients with Ovarian Cancer in Terms of Selected Clinico-pathological Factors

Overview

Journal Contemp Oncol (Pozn)

Publisher Termedia

Specialty Oncology

Date 2013 Jun 22

PMID 23788939

Citations 1

Authors

Anita Chudecka-Glaz

Izabella Rzepka-Gorska

Affiliations

Soon will be listed here.

Abstract

Aim Of The Study: The CD30L ligand is a membrane-associated glycoprotein expressed by activated CD4(+)Th cells, macrophages, dendritic cells, and B lymphocytes. It binds to the CD30 receptor carried on activated and helper Th cells, inducing the immune response and apoptosis. The aim of this retrospective study was to determine the level of sCD30L in the serum of patients at diagnosis of ovarian cancer and at relapse and to assess the potential association of this ligand with selected clinico-pathologic factors.

Material And Methods: We studied 69 patients with ovarian cancer allocated to two groups: A - ovarian cancer at diagnosis, B - relapse of ovarian cancer and active growth of the tumor.

Results: We found high levels of sCD30L in ovarian cancer patients. Levels at relapse (21.48 ng/ml) were significantly higher than at diagnosis (11.81 ng/ml). Poor response to first-line chemotherapy was accompanied by higher levels of sCD30L and by several other findings: resistance to platinum analogs was common, neoadjuvant chemotherapy was needed, relapse and death during two-year follow-up were frequent.

Conclusions: Our present study might initially suggest that elevated concentration of sCD30L can be an important finding prognosticating a poor prognosis and is associated with platinum resistant and refractory cases of ovarian cancer. However, studies are needed on larger groups of patients.

Citing Articles

Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Xue X, Hall M, Zhang Q, Wang P, Gottesman M, Liang X ACS Nano. 2013; 7(12):10452-64.

PMID: 24219825 PMC: 3907077. DOI: 10.1021/nn405004f.

References

Cossu-Rocca P, Jones T, Roth L, Eble J, Zheng W, Abdul Karim F . Cytokeratin and CD30 expression in dysgerminoma. Hum Pathol. 2006; 37(8):1015-21. DOI: 10.1016/j.humpath.2006.02.018. View

Oflazoglu E, Grewal I, Gerber H . Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 2009; 647:174-85. DOI: 10.1007/978-0-387-89520-8_12. View

Han S, Kim Y, Kim T . Role of apoptotic and necrotic cell death under physiologic conditions. BMB Rep. 2008; 41(1):1-10. DOI: 10.5483/bmbrep.2008.41.1.001. View

Purdue M, Lan Q, Martinez-Maza O, Oken M, Hocking W, Huang W . A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood. 2009; 114(13):2730-2. PMC: 2756127. DOI: 10.1182/blood-2009-04-217521. View

Van Cruchten S, Van den Broeck W . Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol. 2002; 31(4):214-23. DOI: 10.1046/j.1439-0264.2002.00398.x. View

McLean K, Shah C, Thompson S, Gray H, Swensen R, Goff B . Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction. Gynecol Oncol. 2010; 118(1):43-6. DOI: 10.1016/j.ygyno.2010.03.002. View

Laskowska M, Laskowska K, Oleszczuk J . Soluble CD30 in normotensive pregnant women with isolated fetal intrauterine growth restriction: a comparison with preeclamptic women. J Reprod Immunol. 2010; 86(2):122-5. DOI: 10.1016/j.jri.2010.05.004. View

Sun X, Yamada H, Shibata K, Muta H, Tani K, Podack E . CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. J Immunol. 2010; 185(12):7671-80. DOI: 10.4049/jimmunol.1002229. View

Horie R, Watanabe T . CD30: expression and function in health and disease. Semin Immunol. 1998; 10(6):457-70. DOI: 10.1006/smim.1998.0156. View

10.

Mielczarek-Palacz A, Kondera-Anasz Z, Sikora J, Sodowski K, Switala J, Kubina R . [Concentration of soluble ligand for receptor CD30 (sCD30L)--marker of apoptosis in women with ovarian tumor]. Ginekol Pol. 2009; 80(7):494-7. View

11.

Lane P, Gaspal F, Kim M . Two sides of a cellular coin: CD4(+)CD3- cells regulate memory responses and lymph-node organization. Nat Rev Immunol. 2005; 5(8):655-60. PMC: 1351344. DOI: 10.1038/nri1665. View

12.

Shimozato O, Takeda K, Yagita H, Okumura K . Expression of CD30 ligand (CD153) on murine activated T cells. Biochem Biophys Res Commun. 1999; 256(3):519-26. DOI: 10.1006/bbrc.1999.0336. View

13.

Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K . Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep. 2005; 13(6):1153-8. View

14.

Kim K, McDonagh C, Westendorf L, Brown L, Sussman D, Feist T . Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther. 2008; 7(8):2486-97. DOI: 10.1158/1535-7163.MCT-08-0388. View

15.

Breen E, Fatahi S, Epeldegui M, Boscardin W, Detels R, Martinez-Maza O . Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol. 2006; 27(4):187-94. DOI: 10.1159/000093022. View

16.

Jurisic V, Srdic-Rajic T, Konjevic G, Bogdanovic G, Colic M . TNF-α induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol. 2011; 239(3):115-22. DOI: 10.1007/s00232-010-9309-7. View

17.

Senter P . Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009; 13(3):235-44. DOI: 10.1016/j.cbpa.2009.03.023. View

18.

Kusanovic J, Romero R, Esoinoza J, Gotsch F, Edwin S, Chaiworapongsa T . Maternal serum soluble CD30 is increased in pregnancies complicated with acute pyelonephritis. J Matern Fetal Neonatal Med. 2007; 20(11):803-11. PMC: 2322879. DOI: 10.1080/14767050701492851. View

19.

Sun X, Yamada H, Shibata K, Muta H, Tani K, Podack E . CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice. J Immunol. 2010; 185(4):2222-30. DOI: 10.4049/jimmunol.1000024. View

20.

Diehl V, Bohlen H, Wolf J . CD30: cytokine-receptor, differentiation marker or a target molecule for specific immune response?. Ann Oncol. 1994; 5(4):300-2. DOI: 10.1093/oxfordjournals.annonc.a058827. View